CD36 down regulation by the macrophage antioxidant 7,8-dihydroneopterin through modulation of PPAR-γ activity

References

• Van Reyk DM, Jessup W. The macrophage in atherosclerosis: modulation of cell function by sterols. J Leukoc Biol. 1999;66(4):557–561.
   PubMed Web of Science ®Google Scholar
• Gieseg SP, Maghzal G, Glubb D. Inhibition of haemolysis by the macrophage synthesized antioxidant, 7,8-dihydroneopterin. Redox Report. 2000;5(2-3):98–100.
   PubMed Web of Science ®Google Scholar
• Endemann G, Stanton LW, Madden KS, et al. CD36 is a receptor for oxidized low-density-lipoprotein. J Biol Chem. 1993;268(16):11811–11816.
   PubMed Web of Science ®Google Scholar
• Nicholson AS, Frieda S, Pearce FA, et al. Oxidised LDL binds to CD36 on human monocyte derived macrophages and transfected cell lines: evidence implicating the lipid moiety of lipoprotein as the binding site. Arterioscler Thromb Vasc Biol. 1995;15(2):269–275.
   PubMed Web of Science ®Google Scholar
• Sheedy FJ, Grebe A, Rayner KJ, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol. 2013;14(8):812–820. +
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Nozaki S, Nishida M, et al. Oxidized LDL increases and interferon-gamma decreases expression of CD36 in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol. 1998;18(8):1350–1357.
   PubMed Web of Science ®Google Scholar
• Gieseg SP, Amit Z, Yang YT, et al. Oxidant production, oxLDL uptake, and CD36 levels in human monocyte derived macrophages are down regulated by the macrophage generated antioxidant 7,8-dihydroneopterin. Antioxid Redox Signal. 2010;13(10):1525–1534.
   PubMed Web of Science ®Google Scholar
• Shchepetkina AA, Hock BD, Miller A, et al. Effect of 7,8-dihydroneopterin mediated CD36 down regulation and oxidant scavenging on oxidised low-density lipoprotein induced cell death in human macrophages. Int J Biochem Cell Biol. 2017;87:27–33.
   PubMed Web of Science ®Google Scholar
• Ghodsian N, Yeandle A, Gieseg SP. Foam cell formation but not oxLDL cytotoxicity is inhibited by CD36 down regulation by the macrophage antioxidant 7,8-dihydroneopterin. Int J Biochem Cell Biol. 2021;133:105918.
   PubMed Web of Science ®Google Scholar
• Ricciarelli R, Zingg JM, Azzi A. Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. Circulation. 2000;102(1):82–87.
   PubMed Web of Science ®Google Scholar
• Yin M, Liu Q, Yu L, et al. Downregulations of CD36 and calpain-1, inflammation, and atherosclerosis by simvastatin in apolipoprotein e knockout mice. J Vasc Res. 2017;54(3):123–130.
   PubMed Web of Science ®Google Scholar
• Pietsch A, Erl W, Lorenz RL. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem Pharmacol. 1996;52(3):433–439.
   PubMed Web of Science ®Google Scholar
• Fuchs D, Hausen A, Reibnegger G, et al. Neopterin as a marker for activated cell-mediated immunity:application in HIV infection. Immunol Today. 1988;9(5):150–155.
   PubMedGoogle Scholar
• Gieseg SP, Leake DS, Flavall EM, et al. Macrophage antioxidant protection within atherosclerotic plaques. Front Biosci (Landmark Ed). 2009;14(4):1230–1246.
   PubMedGoogle Scholar
• Janmale TV, Lindsay A, Gieseg SP. Nucleoside transporters are critical to the uptake and antioxidant activity of 7,8-dihydroneopterin in monocytic cells. Free Radic Res. 2020;54(5):341–350.
   PubMed Web of Science ®Google Scholar
• Gieseg SP, Baxter-Parker G, Lindsay A. Neopterin, inflammation, and oxidative stress: what could we be missing? Antioxidants. 2018;7(7):80.
   Web of Science ®Google Scholar
• Gieseg SP, Whybrow J, Glubb D, et al. Protection of U937 cells from free radical damage by the macrophage synthesized antioxidant 7,8 dihydroneopterin. Free Radic Res. 2001;35(3):311–318.
   PubMed Web of Science ®Google Scholar
• Baird SK, Reid L, Hampton M, et al. OxLDL induced cell death is inhibited by the macrophage synthesised pterin, 7,8-dihydroneopterin, in U937 cells but not THP-1 cells. Biochim Biophys Acta. 2005;1745(3):361–369.
   PubMed Web of Science ®Google Scholar
• Widner B, Mayr C, Wirleitner B, et al. Oxidation of 7,8-Dihydroneopterin by hypochlorous acid yields neopterin. Biochem Biophys Res Commun. 2000;275(2):307–311.
   PubMed Web of Science ®Google Scholar
• Baxter-Parker G, Prebble H, Cross S, et al. Neopterin formation through radical scavenging of superoxide by the macrophage synthesised antioxidant 7,8-dihydroneopterin. Free Radic Biol Med. 2020;152:142–151.
   PubMed Web of Science ®Google Scholar
• Lindsay A, Gieseg SP. Pterins as diagnostic markers of exercise-induced stress: a systematic review. J Sci Med Sport. 2020;23(1):53–62.
   PubMed Web of Science ®Google Scholar
• Sugioka K, Naruko T, Hozumi T, et al. Elevated levels of neopterin are associated with carotid plaques with complex morphology in patients with stable angina pectoris. Atherosclerosis. 2010;208(2):524–530.
   PubMed Web of Science ®Google Scholar
• Janmale T, Genet R, Crone E, et al. Neopterin and 7,8-dihydroneopterin are generated within atherosclerotic plaques. Pteridines. 2015;26(3):93–103.
   Web of Science ®Google Scholar
• Prebble H, Cross S, Marks E, et al. Induced macrophage activation in live excised atherosclerotic plaque. Immunobiology. 2018;223(8-9):526–535.
   PubMed Web of Science ®Google Scholar
• Chawla A, Barak Y, Nagy L, et al. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med. 2001;7(1):48–52.
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Nagy L, Alvarez JG, et al. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93(2):241–252.
   PubMed Web of Science ®Google Scholar
• Nagy L, Tontonoz P, Alvarez JG, et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell. 1998;93(2):229–240.
   PubMed Web of Science ®Google Scholar
• Moore KJ, Rosen ED, Fitzgerald ML, et al. The role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nat Med. 2001;7(1):41–47.
   PubMed Web of Science ®Google Scholar
• Kwok CF, Juan CC, Ho LT. Endothelin-1 decreases CD36 protein expression in vascular smooth muscle cells. Am J Physiol Endocrinol Metab. 2007;292(2):E648–652.
   PubMed Web of Science ®Google Scholar
• Han S, Sidell N. Peroxisome-proliferator-activated-receptor gamma (PPAR gamma) independent induction of CD36 in THP-1 monocytes by retinoic acid. Immunology. 2002;106(1):53–59.
   PubMed Web of Science ®Google Scholar
• Huang JT, Welch JS, Ricote M, et al. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature. 1999;400(6742):378–382.
   PubMed Web of Science ®Google Scholar
• Higashi Y, Peng T, Du J, et al. A redox-sensitive pathway mediates oxidized LDL-induced downregulation of insulin-like growth factor-1 receptor. J Lipid Res. 2005;46(6):1266–1277.
   PubMed Web of Science ®Google Scholar
• Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem. 1999;274(34):23679–23682.
   PubMed Web of Science ®Google Scholar
• Fair A, Pritchard KA. Jr. Oxidized low density lipoprotein increases U937 cell 5-Lipoxygenase activity: Induction of 5-Lipoxygenase activating protein. Biochem Biophys Res Commun. 1994;201(2):1014–1020.
   PubMed Web of Science ®Google Scholar
• Draper HH, Squires EJ, Mahmoodi H, et al. A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials. Free Radic Biol Med. 1993;15(4):353–363.
   PubMed Web of Science ®Google Scholar
• Camp HS, Tafuri SR. Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J Biol Chem. 1997;272(16):10811–10816.
   PubMed Web of Science ®Google Scholar
• Han JH, Hajjar DP, Tauras JM, et al. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma. J Biol Chem. 2000;275(2):1241–1246.
   PubMed Web of Science ®Google Scholar
• Scirpo R, Fiorotto R, Villani A, et al. Stimulation of nuclear receptor peroxisome proliferator-activated receptor-γ limits NF-κB-dependent inflammation in mouse cystic fibrosis biliary epithelium. Hepatology. 2015;62(5):1551–1562.
   PubMed Web of Science ®Google Scholar
• Limor R, Sharon O, Knoll E, et al. Lipoxygenase-derived metabolites are regulators of peroxisome proliferator-activated receptor gamma-2 expression in human vascular smooth muscle cells. Am J Hypertens. 2008;21(2):219–223.
   PubMed Web of Science ®Google Scholar
• Kotla S, Singh NK, Rao GN. ROS via BTK-p300-STAT1-PPARγ signaling activation mediates cholesterol crystals-induced CD36 expression and foam cell formation. Redox Biol. 2017;11:350–364.
   PubMed Web of Science ®Google Scholar
• Gieseg SP, Reibnegger G, Wachter H, et al. 7,8-Dihydroneopterin inhibits low density lipoprotein oxidation in vitro. Evidence that this macrophage secreted pteridine is an antioxidant. Free Radic Res. 1995;23(2): 123–136.
   PubMed Web of Science ®Google Scholar
• Gieseg SP, Cato S. Inhibition of THP-1 cell-mediated low-density lipoprotein oxidation by the macrophage-synthesised pterin, 7,8-dihydroneopterin. Redox Rep. 2003;8(2):113–119.
   PubMed Web of Science ®Google Scholar
• Han J, Hajjar DP, Zhou X, et al. Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression. A new mechanism of action for high density lipoprotein. J Biol Chem. 2002;277(26):23582–23586.
   PubMed Web of Science ®Google Scholar
• Yu M, Jiang M, Chen Y, et al. Inhibition of macrophage CD36 expression and cellular oxidized low density lipoprotein (oxLDL) accumulation by tamoxifen a peroxisome proliferator-activated receptor (PPAR)γ-dependent mechanism. J Biol Chem. 2016;291(33):16977–16989.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Lisanti MP, Scherer PE. Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis. J Biol Chem. 1998;273(48):32111–32120.
   PubMed Web of Science ®Google Scholar
• Zhao M, Liu Y, Wang X, et al. Activation of the p38 MAP kinase pathway is required for foam cell formation from macrophages exposed to oxidized LDL. APMIS. 2002;110(6):458–468.
   PubMed Web of Science ®Google Scholar
• Puigserver P, Rhee J, Lin J, et al. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell. 2001;8(5):971–982.
   PubMed Web of Science ®Google Scholar
• Prigge ST, Boyington JC, Faig M, et al. Structure and mechanism of lipoxygenases. Biochimie. 1997;79(11):629–636.
   PubMed Web of Science ®Google Scholar
• Pein H, Ville A, Pace S, et al. Endogenous metabolites of vitamin E limit inflammation by targeting 5-lipoxygenase. Nat Commun. 2018;9(1):3834.
   PubMedGoogle Scholar
• Gieseg SP, Glubb D, Maghzal G. Protection of erythrocytes by the macrophage synthesized antioxidant 7,8 dihydroneopterin. Free Radic Res. 2001;34(2):123–136.
   PubMed Web of Science ®Google Scholar
• Gieseg SP, Pearson J, Firth CA. Protein hydroperoxides are a major product of low density lipoprotein oxidation during copper, peroxyl radical and macrophage-mediated oxidation. Free Radic Res. 2003;37(9):983–991.
   PubMed Web of Science ®Google Scholar
• Yang YT, Whiteman M, Gieseg SP. Intracellular glutathione protects human monocyte-derived macrophages from hypochlorite damage. Life Sci. 2012;90(17-18):682–688.
   PubMed Web of Science ®Google Scholar
• Huo Y, Zhao L, Hyman MC, et al. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004;110(14):2024–2031.
   PubMed Web of Science ®Google Scholar
• Bäck M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther. 2009;23(1):41–48.
   PubMed Web of Science ®Google Scholar
• Baxter-Parker G, Gaddam RR, Moltchanova E, et al. Oxidative stress and immune cell activation quantification in sepsis and non-sepsis critical care patients by neopterin/7,8-dihydroneopterin analysis. Pteridines. 2020;31(1):68–82.
   Web of Science ®Google Scholar
• Baydar T, Yuksel O, Sahin TT, et al. Neopterin as a prognostic biomarker in intensive care unit patients. J. Crit. Care. 2009;24(3):318–321.
   PubMed Web of Science ®Google Scholar
• Adachi T, Naruko T, Itoh A, et al. Neopterin is associated with plaque inflammation and destabilisation in human coronary atherosclerotic lesions. Heart. 2006;93(12):1537–1541.
   Web of Science ®Google Scholar
• Marks ECA, Wilkinson TM, Frampton CM, et al. Plasma levels of soluble VEGF receptor isoforms, circulating pterins and VEGF system SNPs as prognostic biomarkers in patients with acute coronary syndromes. BMC Cardiovasc Disord. 2018;18:169.
   PubMed Web of Science ®Google Scholar
• Signorelli SS, Anzaldi M, Fiore V, et al. Neopterin: a potential marker in chronic peripheral arterial disease. Mol Med Rep. 2013;7(6):1855–1858.
   PubMed Web of Science ®Google Scholar
• Ko YG, Le VC, Kim BH, et al. Correlations between coronary plaque tissue composition assessed by virtual histology and blood levels of biomarkers for coronary artery disease. Yonsei Med J. 2012;53(3):508–516.
   PubMed Web of Science ®Google Scholar
• Handberg A, Skjelland M, Michelsen AE, et al. Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability. Stroke. 2008;39(11):3092–3095.
   PubMed Web of Science ®Google Scholar
• Isoviita PM, Nuotio K, Saksi J, et al. An imbalance between CD36 and ABCA1 protein expression favors lipid accumulation in stroke-prone ulcerated carotid plaques. Stroke. 2010;41(2):389–393.
   PubMed Web of Science ®Google Scholar